TransCode Therapeutics, Inc.
RNAZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5 | $13 | $51 | $0 |
| Gross Profit | -$5 | -$13 | -$51 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,156 | $2,566 | $2,206 | $3,638 |
| G&A Expenses | $0 | $1,655 | $0 | $1,454 |
| SG&A Expenses | $1,400 | $1,655 | $914 | $1,454 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,556 | $4,221 | $3,120 | $5,092 |
| Operating Income | -$4,561 | -$4,221 | -$3,171 | -$5,092 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$295 | -$55 | -$8,914 | -$824 |
| Pre-Tax Income | -$4,856 | -$4,277 | -$12,085 | -$5,916 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,856 | -$4,277 | -$12,085 | -$5,916 |
| % Margin | – | – | – | – |
| EPS | -5,824.82 | -5.13 | -70.28 | -16.61 |
| % Growth | -113,444.2% | 92.7% | -323.1% | – |
| EPS Diluted | -5,824.82 | -5.13 | -70.28 | -16.61 |
| Weighted Avg Shares Out | 834 | 834 | 172 | 356 |
| Weighted Avg Shares Out Dil | 834 | 834 | 172 | 356 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6 | $0 | $0 | $2 |
| Depreciation & Amortization | $5 | $13 | $51 | $123 |
| EBITDA | -$4,845 | -$4,263 | -$12,034 | -$5,791 |
| % Margin | – | – | – | – |